{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T23:32:01Z","timestamp":1777246321233,"version":"3.51.4"},"publisher-location":"Singapore","reference-count":137,"publisher":"Springer Nature Singapore","isbn-type":[{"value":"9789819568710","type":"print"},{"value":"9789819568727","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-981-95-6872-7_25","type":"book-chapter","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:32:41Z","timestamp":1777242761000},"page":"429-449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychedelics: Future Therapeutics in Major Depression?"],"prefix":"10.1007","author":[{"given":"Berend","family":"Olivier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelien D. A.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"1","key":"25_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1176\/appi.ajp.20231063","volume":"182","author":"ST Aaronson","year":"2025","unstructured":"Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A et al (2025) Single-dose psilocybin for depression with severe treatment resistance: an open-label trial. Am J Psychiatry 182(1):104\u2013113. https:\/\/doi.org\/10.1176\/appi.ajp.20231063","journal-title":"Am J Psychiatry"},{"issue":"10","key":"25_CR2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40263-023-01032-5","volume":"37","author":"D Akbar","year":"2023","unstructured":"Akbar D, Rhee TG, Ceban F, Ho R, Teopiz KM, Cao B et al (2023) Dextromethorphan-bupropion for the treatment of depression: a systematic review of efficacy and safety in clinical trials. CNS Drugs 37(10):867\u2013881. https:\/\/doi.org\/10.1007\/s40263-023-01032-5","journal-title":"CNS Drugs"},{"key":"25_CR3","doi-asserted-by":"publisher","unstructured":"Andrade C (2023a) Ketamine for depression-knowns, unknowns, possibilities, barriers, and opportunities. JAMA Psychiatry. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.3982","DOI":"10.1001\/jamapsychiatry.2023.3982"},{"issue":"4","key":"25_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/acps.13617","volume":"148","author":"C Andrade","year":"2023","unstructured":"Andrade C (2023b) The not so little matter of how to dose ketamine in patients with depression. Acta Psychiatr Scand 148(4):313\u2013315. https:\/\/doi.org\/10.1111\/acps.13617","journal-title":"Acta Psychiatr Scand"},{"issue":"12","key":"25_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49026","volume":"7","author":"AL Back","year":"2024","unstructured":"Back AL, Freeman-Young TK, Morgan L, Sethi T, Baker KK, Myers S et al (2024) psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: a randomized clinical trial. JAMA Netw Open 7(12):e2449026. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.49026","journal-title":"JAMA Netw Open"},{"issue":"1","key":"25_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2023.2278586","volume":"57","author":"A Bahji","year":"2025","unstructured":"Bahji A, Lunsky I, Gutierrez G, Vazquez G (2025) Efficacy and safety of four psychedelic-assisted therapies for adults with symptoms of depression, anxiety, and posttraumatic stress disorder: a systematic review and meta-analysis. J Psychoactive Drugs 57(1):1\u201316. https:\/\/doi.org\/10.1080\/02791072.2023.2278586","journal-title":"J Psychoactive Drugs"},{"key":"25_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jpsychires.2023.06.028","volume":"164","author":"ID Bandeira","year":"2023","unstructured":"Bandeira ID, Leal GC, Correia-Melo FS, Souza-Marques B, Silva SS, Lins-Silva DH et al (2023) Arketamine for bipolar depression: open-label, dose-escalation, pilot study. J Psychiatr Res 164:229\u2013234. https:\/\/doi.org\/10.1016\/j.jpsychires.2023.06.028","journal-title":"J Psychiatr Res"},{"issue":"4","key":"25_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/jamapsychiatry.2024.4787","volume":"82","author":"BS Barnett","year":"2025","unstructured":"Barnett BS, Weiss RD, Sanacora G (2025) Strengthening safeguards for psychiatric uses of ketamine. JAMA Psychiatry 82(4):333\u2013334. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.4787","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"25_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47(4):351\u2013354. https:\/\/doi.org\/10.1016\/s0006-3223(99)00230-9","journal-title":"Biol Psychiatry"},{"key":"25_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-90","volume":"9","author":"E Bromet","year":"2011","unstructured":"Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G et al (2011) Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 9:90. https:\/\/doi.org\/10.1186\/1741-7015-9-90","journal-title":"BMC Med"},{"key":"25_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pbr.2018.09.013","volume":"242","author":"T Calvey","year":"2018","unstructured":"Calvey T, Howells FM (2018) An introduction to psychedelic neuroscience. Prog Brain Res 242:1\u201323. https:\/\/doi.org\/10.1016\/bs.pbr.2018.09.013","journal-title":"Prog Brain Res"},{"issue":"45","key":"25_CR12","doi-asserted-by":"publisher","first-page":"7472","DOI":"10.1523\/JNEUROSCI.1384-23.2023","volume":"43","author":"LP Cameron","year":"2023","unstructured":"Cameron LP, Benetatos J, Lewis V, Bonniwell EM, Jaster AM, Moliner R et al (2023a) Beyond the 5-HT2A receptor: classic and nonclassic targets in psychedelic drug action. J Neurosci 43(45):7472\u20137482. https:\/\/doi.org\/10.1523\/JNEUROSCI.1384-23.2023","journal-title":"J Neurosci"},{"issue":"3","key":"25_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1021\/acschemneuro.2c00718","volume":"14","author":"LP Cameron","year":"2023","unstructured":"Cameron LP, Patel SD, Vargas MV, Barragan EV, Saeger HN, Warren HT et al (2023b) 5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines. ACS Chem Neurosci 14(3):351\u2013358. https:\/\/doi.org\/10.1021\/acschemneuro.2c00718","journal-title":"ACS Chem Neurosci"},{"issue":"Pt 1","key":"25_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","volume":"126","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Gatch MB (2016) Neuropharmacology of N,N-dimethyltryptamine. Brain Res Bull 126(Pt 1):74\u201388. https:\/\/doi.org\/10.1016\/j.brainresbull.2016.04.016","journal-title":"Brain Res Bull"},{"issue":"7","key":"25_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M et al (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3(7):619\u2013627. https:\/\/doi.org\/10.1016\/S2215-0366(16)30065-7","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"25_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE et al (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235(2):399\u2013408. https:\/\/doi.org\/10.1007\/s00213-017-4771-x","journal-title":"Psychopharmacology"},{"issue":"15","key":"25_CR17","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R et al (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384(15):1402\u20131411. https:\/\/doi.org\/10.1056\/NEJMoa2032994","journal-title":"N Engl J Med"},{"key":"25_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jad.2020.03.106","volume":"271","author":"L Citrome","year":"2020","unstructured":"Citrome L, DiBernardo A, Singh J (2020) Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 271:228\u2013238. https:\/\/doi.org\/10.1016\/j.jad.2020.03.106","journal-title":"J Affect Disord"},{"key":"25_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jpsychires.2024.03.002","volume":"173","author":"M Colla","year":"2024","unstructured":"Colla M, Offenhammer B, Scheerer H, Kronenberg G, Vetter S, Mutschler J et al (2024) Oral prolonged-release ketamine in treatment-resistant depression\u2014a double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation\u2014clinical and safety results. J Psychiatr Res 173:124\u2013130. https:\/\/doi.org\/10.1016\/j.jpsychires.2024.03.002","journal-title":"J Psychiatr Res"},{"key":"25_CR20","doi-asserted-by":"publisher","unstructured":"Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatr 2019;76(9):893\u2013903. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1189, https:\/\/doi.org\/10.1056\/NEJMoa2032994","DOI":"10.1001\/jamapsychiatry.2019.1189"},{"issue":"5","key":"25_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2021) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78(5):481\u2013489. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","journal-title":"JAMA Psychiatry"},{"key":"25_CR22","doi-asserted-by":"publisher","unstructured":"Del Casale A, Spirito S, Arena JF, Preissner S, Borro M, Gentile G et al (2025) Esketamine combined with SSRI or SNRI for treatment-resistant depression. JAMA Psychiatr:e250200. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0200","DOI":"10.1001\/jamapsychiatry.2025.0200"},{"issue":"4","key":"25_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/00002018-200023040-00003","volume":"23","author":"V Dev","year":"2000","unstructured":"Dev V, Raniwalla J (2000) Quetiapine: a review of its safety in the management of schizophrenia. Drug Saf 23(4):295\u2013307. https:\/\/doi.org\/10.2165\/00002018-200023040-00003","journal-title":"Drug Saf"},{"issue":"Pt 1","key":"25_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.brainresbull.2016.03.002","volume":"126","author":"E Dom\u00ednguez-Clav\u00e9","year":"2016","unstructured":"Dom\u00ednguez-Clav\u00e9 E, Soler J, Elices M, Pascual JC, \u00c1lvarez E, de la Fuente Revenga M et al (2016) Ayahuasca: pharmacology, neuroscience and therapeutic potential. Brain Res Bull 126(Pt 1):89\u2013101. https:\/\/doi.org\/10.1016\/j.brainresbull.2016.03.002","journal-title":"Brain Res Bull"},{"issue":"1","key":"25_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nm.4246","volume":"23","author":"AT Drysdale","year":"2017","unstructured":"Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y et al (2017) Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med 23(1):28\u201338. https:\/\/doi.org\/10.1038\/nm.4246","journal-title":"Nat Med"},{"key":"25_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jad.2024.09.133","volume":"369","author":"S Ellis","year":"2025","unstructured":"Ellis S, Bostian C, Feng W, Fischer E, Schwartz G, Eisen K et al (2025) Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression\u2014a first-in-kind open-label pilot study. J Affect Disord 369:381\u2013389. https:\/\/doi.org\/10.1016\/j.jad.2024.09.133","journal-title":"J Affect Disord"},{"issue":"1","key":"25_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2344\/0003-3006(2007)54[9:AIUTAO]2.0.CO;2","volume":"54","author":"DE Emmanouil","year":"2007","unstructured":"Emmanouil DE, Quock RM (2007) Advances in understanding the actions of nitrous oxide. Anesth Prog 54(1):9\u201318. https:\/\/doi.org\/10.2344\/0003-3006(2007)54[9:AIUTAO]2.0.CO;2","journal-title":"Anesth Prog"},{"key":"25_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2025.111249","volume":"136","author":"I Erkizia-Santamar\u00eda","year":"2025","unstructured":"Erkizia-Santamar\u00eda I, Horrillo I, Meana JJ, Ortega JE (2025) Prog Neuro-Psychopharmacol Biol Psychiatry 136:111249. https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111249","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"7","key":"25_CR29","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5.79","volume":"25","author":"M Fava","year":"2020","unstructured":"Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C et al (2020) Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry 25(7):1592\u20131603. https:\/\/doi.org\/10.1038\/s41380-018-0256-5.79","journal-title":"Mol Psychiatry"},{"issue":"7","key":"25_CR30","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00406-023-01571-4","volume":"273","author":"M Fava","year":"2023","unstructured":"Fava M, Stahl SM, De Martin S, Mattarei A, Bettini E, Comai S et al (2023) Esmethadone-HCl (REL-1017): a promising rapid antidepressant. Eur Arch Psychiatry Clin Neurosci 273(7):1463\u20131476. https:\/\/doi.org\/10.1007\/s00406-023-01571-4","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"10","key":"25_CR31","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","volume":"22","author":"M Fedgchin","year":"2019","unstructured":"Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P et al (2019) Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol 22(10):616\u2013630. https:\/\/doi.org\/10.1093\/ijnp\/pyz039","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"25_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.psc.2023.02.003","volume":"46","author":"A Feeney","year":"2023","unstructured":"Feeney A, Papakostas GI (2023) Pharmacotherapy: ketamine and esketamine. Psychiatr Clin North Am 46(2):277\u2013290. https:\/\/doi.org\/10.1016\/j.psc.2023.02.003","journal-title":"Psychiatr Clin North Am"},{"issue":"3","key":"25_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1176\/appi.ajp.20240515","volume":"182","author":"KN Fountoulakis","year":"2025","unstructured":"Fountoulakis KN, Saitis A, Schatzberg AF (2025) Esketamine treatment for depression in adults: a PRISMA systematic review and meta-analysis. Am J Psychiatry 182(3):259\u2013275. https:\/\/doi.org\/10.1176\/appi.ajp.20240515","journal-title":"Am J Psychiatry"},{"issue":"6","key":"25_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014912","volume":"7","author":"G Gartlehner","year":"2017","unstructured":"Gartlehner G, Wagner G, Matyas N, Titscher V, Greimel J, Lux L et al (2017) Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews. BMJ Open 7(6):e014912. https:\/\/doi.org\/10.1136\/bmjopen-2016-014912","journal-title":"BMJ Open"},{"key":"25_CR35","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796019000751","volume":"29","author":"C Gastaldon","year":"2019","unstructured":"Gastaldon C, Papola D, Ostuzzi G, Barbui C (2019) Esketamine for treatment resistant depression: a trick of smoke and mirrors? Epidemiol Psychiatr Sci 29:e79. https:\/\/doi.org\/10.1017\/S2045796019000751","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"10159","key":"25_CR36","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD","year":"2018","unstructured":"GBD (2018) 2017: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Lancet. 392(10159):1789\u20131858. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7","journal-title":"Lancet."},{"issue":"1","key":"25_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0378-4347(91)80350-l","volume":"568","author":"G Geisslinger","year":"1991","unstructured":"Geisslinger G, Menzel-Soglowek S, Kamp HD, Brune K (1991) Stereoselective high-performance liquid chromatographic determination of the enantiomers of ketamine and norketamine in plasma. J Chromatogr 568(1):165\u2013176. https:\/\/doi.org\/10.1016\/0378-4347(91)80350-l","journal-title":"J Chromatogr"},{"issue":"4","key":"25_CR38","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/bja\/75.4.506","volume":"75","author":"G Geisslinger","year":"1995","unstructured":"Geisslinger G, Hering W, Kamp HD, Vollmers KO (1995) Pharmacokinetics of ketamine enantiomers. Br J Anaesth 75(4):506\u2013507. https:\/\/doi.org\/10.1093\/bja\/75.4.506","journal-title":"Br J Anaesth"},{"issue":"1","key":"25_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1017\/S1092852921000791","volume":"28","author":"X Gonda","year":"2023","unstructured":"Gonda X, Dome P, Neill JC, Tarazi FI (2023) Novel antidepressant drugs: beyond monoamine targets. CNS Spectr 28(1):6\u201315. https:\/\/doi.org\/10.1017\/S1092852921000791","journal-title":"CNS Spectr"},{"issue":"18","key":"25_CR40","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC et al (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 387(18):1637\u20131648. https:\/\/doi.org\/10.1056\/NEJMoa2206443","journal-title":"N Engl J Med"},{"key":"25_CR41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jad.2023.01.108","volume":"327","author":"GM Goodwin","year":"2023","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M et al (2023) Single-dose psilocybin for a treatment-resistant episode of major depression: impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord 327:120\u2013127. https:\/\/doi.org\/10.1016\/j.jad.2023.01.108","journal-title":"J Affect Disord"},{"issue":"6","key":"25_CR42","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/026988110809430021","volume":"22","author":"R Griffiths","year":"2008","unstructured":"Griffiths R, Richards W, Johnson M, McCann U, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22(6):621\u2013632. https:\/\/doi.org\/10.1177\/026988110809430021","journal-title":"J Psychopharmacol"},{"issue":"5","key":"25_CR43","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1590\/1516-4446-2020-1543","volume":"43","author":"MC Guimar\u00e3es","year":"2021","unstructured":"Guimar\u00e3es MC, Guimar\u00e3es TM, Hallak JE, Abr\u00e3o J, Machado-de-Sousa JP (2021) Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial. Braz J Psychiatry 43(5):484\u2013493. https:\/\/doi.org\/10.1590\/1516-4446-2020-1543","journal-title":"Braz J Psychiatry"},{"key":"25_CR44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36(2)","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW et al (2022) Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol 36(2):151\u2013158. https:\/\/doi.org\/10.1177\/02698811211073759","journal-title":"J Psychopharmacol"},{"issue":"1","key":"25_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-024-06448-x","volume":"25","author":"K Halpape","year":"2025","unstructured":"Halpape K, Pashovitz R, Wanson A, Hooper M, Peters EM (2025) Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant depression: a naturalistic feasibility study. BMC Psychiatry 25(1):23. https:\/\/doi.org\/10.1186\/s12888-024-06448-x","journal-title":"BMC Psychiatry"},{"issue":"12","key":"25_CR46","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn I (2016) Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol 30(12):1259\u20131267. https:\/\/doi.org\/10.1177\/0269881116677852","journal-title":"J Psychopharmacol"},{"issue":"2","key":"25_CR47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 172(2):145\u2013156. https:\/\/doi.org\/10.1007\/s00213-003-1640-6","journal-title":"Psychopharmacology"},{"key":"25_CR48","doi-asserted-by":"publisher","DOI":"10.1177\/24705470211020446","volume":"5","author":"J Hecking","year":"2021","unstructured":"Hecking J, Davoudian PA, Wilkinson ST (2021) Emerging therapeutics based on the amino acid neurotransmitter system: an update on the pharmaceutical pipeline for mood disorders. Chronic Stress (Thousand Oaks) 5:24705470211020446. https:\/\/doi.org\/10.1177\/24705470211020446","journal-title":"Chronic Stress (Thousand Oaks)"},{"issue":"5","key":"25_CR49","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-021-00816-x","volume":"35","author":"ID Henter","year":"2021","unstructured":"Henter ID, Park LT, Zarate CA Jr (2021) Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs 35(5):527\u2013543. https:\/\/doi.org\/10.1007\/s40263-021-00816-x","journal-title":"CNS Drugs"},{"issue":"5","key":"25_CR50","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1192\/bjp.2020.89","volume":"219","author":"MA Horowitz","year":"2021","unstructured":"Horowitz MA, Moncrieff J (2021) Are we repeating mistakes of the past? a review of the evidence for esketamine. Br J Psychiatry 219(5):614\u2013617. https:\/\/doi.org\/10.1192\/bjp.2020.89","journal-title":"Br J Psychiatry"},{"issue":"1\u20132","key":"25_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejphar.2005.01.018","volume":"510","author":"ZA Hughes","year":"2005","unstructured":"Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ et al (2005) Neurochemical evaluation of the novel 5-HT1A receptor partial agonist\/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 510(1\u20132):49\u201357. https:\/\/doi.org\/10.1016\/j.ejphar.2005.01.018","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"25_CR52","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jamapsychiatry.2025.0085","volume":"82","author":"NTM Huneke","year":"2025","unstructured":"Huneke NTM, Fusetto Veronesi G, Garner M, Baldwin DS, Cortese S (2025) Expectancy effects, failure of blinding integrity, and placebo response in trials of treatments for psychiatric disorders: a narrative review. JAMA Psychiatry 82(5):531\u2013538. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0085","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"25_CR53","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2858","volume":"8","author":"PR Hutson","year":"2025","unstructured":"Hutson PR (2025) Psilocybin dispensaries and advertising-buyer beware. JAMA Netw Open 8(4):e252858. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.2858","journal-title":"JAMA Netw Open"},{"issue":"4","key":"25_CR54","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14345","volume":"83","author":"DV Iosifescu","year":"2022","unstructured":"Iosifescu DV, Jones A, O'Gorman C, Streicher C, Feliz S, Fava M et al (2022) Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry 83(4):21m14345","journal-title":"J Clin Psychiatry"},{"key":"25_CR55","unstructured":"Jacobs A (2024) FDA declines to approve MDMA therapy, seeking more study. The New York Times, section A:16"},{"issue":"2","key":"25_CR56","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/0269881120959644","volume":"35","author":"LA Jelen","year":"2021","unstructured":"Jelen LA, Young AH, Stone JM (2021) Ketamine: a tale of two enantiomers. J Psychopharmacol 35(2):109\u2013123. https:\/\/doi.org\/10.1177\/0269881120959644","journal-title":"J Psychopharmacol"},{"key":"25_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108431","volume":"246","author":"JN Johnston","year":"2023","unstructured":"Johnston JN, Henter ID, Zarate CA Jr (2023a) The antidepressant actions of ketamine and its enantiomers. Pharmacol Ther 246:108431. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108431","journal-title":"Pharmacol Ther"},{"key":"25_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109422","volume":"226","author":"JN Johnston","year":"2023","unstructured":"Johnston JN, Kadriu B, Allen J, Gilbert JR, Henter ID, Zarate CA Jr (2023b) Ketamine and serotonergic psychedelics: an update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology 226:109422. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109422","journal-title":"Neuropharmacology"},{"issue":"2","key":"25_CR59","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.psc.2023.02.004","volume":"46","author":"S Kamal","year":"2023","unstructured":"Kamal S, Jha MK, Radhakrishnan R (2023) Role of psychedelics in treatment-resistant depression. Psychiatr Clin North Am 46(2):291\u2013305. https:\/\/doi.org\/10.1016\/j.psc.2023.02.004","journal-title":"Psychiatr Clin North Am"},{"issue":"10","key":"25_CR60","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3390\/biomedicines12102283","volume":"12","author":"P Kawczak","year":"2024","unstructured":"Kawczak P, Feszak I, B\u0105czek T (2024) Ketamine, esketamine, and arketamine: their mechanisms of action and applications in the treatment of depression and alleviation of depressive symptoms. Biomedicine 12(10):2283. https:\/\/doi.org\/10.3390\/biomedicines12102283","journal-title":"Biomedicine"},{"issue":"11","key":"25_CR61","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40263-022-00968-4","volume":"36","author":"SJ Keam","year":"2022","unstructured":"Keam SJ (2022) Dextromethorphan\/bupropion: first approval. CNS Drugs 36(11):1229\u20131238. https:\/\/doi.org\/10.1007\/s40263-022-00968-4","journal-title":"CNS Drugs"},{"key":"25_CR62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-publhealth-031912-114409","volume":"34","author":"RC Kessler","year":"2013","unstructured":"Kessler RC, Bromet EJ (2013) The epidemiology of depression across cultures. Annu Rev Public Health 34:119\u2013138. https:\/\/doi.org\/10.1146\/annurev-publhealth-031912-114409","journal-title":"Annu Rev Public Health"},{"issue":"12","key":"25_CR63","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","volume":"76","author":"KA Lapidus","year":"2014","unstructured":"Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L et al (2014) A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 76(12):970\u2013976. https:\/\/doi.org\/10.1016\/j.biopsych.2014.03.026","journal-title":"Biol Psychiatry"},{"issue":"3","key":"25_CR64","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","volume":"271","author":"GC Leal","year":"2021","unstructured":"Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F et al (2021) Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci 271(3):577\u2013582. https:\/\/doi.org\/10.1007\/s00406-020-01110-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"330","key":"25_CR65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jad.2023.02.151","volume":"1","author":"GC Leal","year":"2023","unstructured":"Leal GC, Souza-Marques B, Mello RP, Bandeira ID, Caliman-Fontes AT, Carneiro BA, Faria-Guimar\u00e3es D, Guerreiro-Costa LNF, Jesus-Nunes AP, Silva SS, Lins-Silva DH, Fontes MA, Alves-Pereira R, Cordeiro V, Rugieri-Pacheco S, Santos-Lima C, Correia-Melo FS, Vieira F, Sanacora G, Lacerda ALT, Quarantini LC (2023 Jun) Arketamine as adjunctive therapy for treatment-resistant depression: a placebo-controlled pilot study. J Affect Disord 1(330):7\u201315. https:\/\/doi.org\/10.1016\/j.jad.2023.02.151","journal-title":"J Affect Disord"},{"key":"25_CR66","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuropharm.2017.04.017","volume":"121","author":"Y Li","year":"2017","unstructured":"Li Y, Pehrson AL, Oosting RS, Gulinello M, Olivier B, Sanchez C (2017) A study of time- and sex-dependent effects of vortioxetine on rat sexual behavior: possible roles of direct receptor modulation. Neuropharmacology 121:89\u201399. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.04.017","journal-title":"Neuropharmacology"},{"key":"25_CR67","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41583-024-00876-0","volume":"26(2)","author":"C Liao","year":"2025","unstructured":"Liao C, Dua AN, Wojtasiewicz C, Liston C, Kwan AC (2025) Structural neural plasticity evoked by rapid-acting antidepressant interventions. Nat Rev Neurosci 26(2):101\u2013114. https:\/\/doi.org\/10.1038\/s41583-024-00876-0","journal-title":"Nat Rev Neurosci"},{"key":"25_CR68","unstructured":"Loftus P (2024) J&J\u2019s ketamine derived drug is taken off. Wall Street J. October 1; 2024"},{"issue":"10161","key":"25_CR69","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","volume":"392","author":"GS Mahli","year":"2018","unstructured":"Mahli GS, Mann JJ (2018) Depression. Lancet 392(10161):2299\u20132312. https:\/\/doi.org\/10.1016\/S0140-6736(18)31948-2","journal-title":"Lancet"},{"key":"25_CR70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.euroneuro.2022.10.008","volume":"66","author":"LO Maia","year":"2023","unstructured":"Maia LO, Daldegan-Bueno D, Wie\u00dfner I, Araujo DB, T\u00f3foli LF (2023) Ayahuasca\u2019s therapeutic potential: what we know\u2014and what not. Eur Neuropsychopharmacol 66:45\u201361. https:\/\/doi.org\/10.1016\/j.euroneuro.2022.10.008","journal-title":"Eur Neuropsychopharmacol"},{"key":"25_CR71","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","volume":"277","author":"WS Marcantoni","year":"2020","unstructured":"Marcantoni WS, Akoumba BS, Wassef M, Mayrand J, Lai H, Richard-Devantoy S et al (2020) A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009\u2014January 2019. J Affect Disord 277:831\u2013841. https:\/\/doi.org\/10.1016\/j.jad.2020.09.007","journal-title":"J Affect Disord"},{"issue":"10371","key":"25_CR72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0140-6736(22)02080-3","volume":"401","author":"S Marwaha","year":"2023","unstructured":"Marwaha S, Palmer E, Suppes T, Cons E, Young AH, Upthegrove R (2023) Novel and emerging treatments for major depression. Lancet 401(10371):141\u2013153. https:\/\/doi.org\/10.1016\/S0140-6736(22)02080-3","journal-title":"Lancet"},{"issue":"3","key":"25_CR73","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1176\/appi.ajp.20241177","volume":"182","author":"SJ Mathew","year":"2025","unstructured":"Mathew SJ, Murphy N (2025) Six years after approval of esketamine nasal spray for serious depression: clinical conundrums and unanswered questions. Am J Psychiatry 182(3):227\u2013230. https:\/\/doi.org\/10.1176\/appi.ajp.20241177","journal-title":"Am J Psychiatry"},{"issue":"4","key":"25_CR74","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2853","volume":"8","author":"J Matsukubo","year":"2025","unstructured":"Matsukubo J, Dickson S, Xiao J, Friesen EL, Solmi M, Jess G et al (2025) Psilocybin dispensaries and online health claims in Canada. JAMA Netw Open 8(4):e252853. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.2853","journal-title":"JAMA Netw Open"},{"issue":"4","key":"25_CR75","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1017\/S0033291714001603","volume":"45","author":"A McGirr","year":"2015","unstructured":"McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW (2015) A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 45(4):693\u2013704. https:\/\/doi.org\/10.1017\/S0033291714001603","journal-title":"Psychol Med"},{"key":"25_CR76","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","volume":"276","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Carvalho IP, Lui LMW, Majeed A, Masand PS, Gill H et al (2020) The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis. J Affect Disord 276:576\u2013584. https:\/\/doi.org\/10.1016\/j.jad.2020.06.050","journal-title":"J Affect Disord"},{"issue":"5","key":"25_CR77","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M et al (2021) Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry 178(5):383\u2013399. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20081251","journal-title":"Am J Psychiatry"},{"issue":"3","key":"25_CR78","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF et al (2023) Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry 22(3):394\u2013412. https:\/\/doi.org\/10.1002\/wps.21120","journal-title":"World Psychiatry"},{"key":"25_CR79","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1176\/appi.ajp.20230902","volume":"182","author":"RS McIntyre","year":"2025","unstructured":"McIntyre RS, Kwan ATH, Mansur RB, Oliveira-Maia AJ, Teopiz KM, Maletic V et al (2025) Psychedelics for the treatment of psychiatric disorders: interpreting and translating available evidence and guidance for future research. Am J Psychiatry 182:21\u201332. https:\/\/doi.org\/10.1176\/appi.ajp.20230902","journal-title":"Am J Psychiatry"},{"issue":"2","key":"25_CR80","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0378-8741(84)90003-5","volume":"10","author":"DJ McKenna","year":"1984","unstructured":"McKenna DJ, Towers GH, Abbott F (1984) Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca. J Ethnopharmacol 10(2):195\u2013223. https:\/\/doi.org\/10.1016\/0378-8741(84)90003-5","journal-title":"J Ethnopharmacol"},{"issue":"9","key":"25_CR81","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/EJA.0000000000000638","volume":"34","author":"G Mion","year":"2017","unstructured":"Mion G (2017) History of anaesthesia: the ketamine story\u2014past, present and future. Eur J Anaesthesiol 34(9):571\u2013575. https:\/\/doi.org\/10.1097\/EJA.0000000000000638","journal-title":"Eur J Anaesthesiol"},{"issue":"10","key":"25_CR82","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/s0006-3223(01)01362-2","volume":"51","author":"B Moghaddam","year":"2002","unstructured":"Moghaddam B (2002) Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry 51(10):775\u2013787. https:\/\/doi.org\/10.1016\/s0006-3223(01)01362-2","journal-title":"Biol Psychiatry"},{"issue":"10","key":"25_CR83","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","volume":"170","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM et al (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170(10):1134\u20131142. https:\/\/doi.org\/10.1176\/appi.ajp.2013.13030392","journal-title":"Am J Psychiatry"},{"key":"25_CR84","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jad.2017.04.072","volume":"218","author":"JW Murrough","year":"2017","unstructured":"Murrough JW, Wade E, Sayed S, Ahle G, Kiraly DD, Welch A et al (2017) Dextromethorphan\/quinidine pharmacotherapy in patients with treatment resistant depression: a proof of concept clinical trial. J Affect Disord 218:277\u2013283. https:\/\/doi.org\/10.1016\/j.jad.2017.04.072","journal-title":"J Affect Disord"},{"issue":"1","key":"25_CR85","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.biopsych.2014.11.016","volume":"78","author":"P Nagele","year":"2015","unstructured":"Nagele P, Duma A, Kopec M, Gebara MA, Parsoei A, Walker M et al (2015) Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial. Biol Psychiatry 78(1):10\u201318. https:\/\/doi.org\/10.1016\/j.biopsych.2014.11.016","journal-title":"Biol Psychiatry"},{"issue":"597","key":"25_CR86","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe1376","volume":"13","author":"P Nagele","year":"2021","unstructured":"Nagele P, Palanca BJ, Gott B, Brown F, Barnes L, Nguyen T et al (2021) A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression. Sci Transl Med 13(597):eabe1376. https:\/\/doi.org\/10.1126\/scitranslmed.abe1376","journal-title":"Sci Transl Med"},{"issue":"2","key":"25_CR87","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev. 68(2):264\u2013356. https:\/\/doi.org\/10.1124\/pr.115.011478","journal-title":"Pharmacol Rev."},{"issue":"3","key":"25_CR88","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/S0022-3565(25)38235-2","volume":"265","author":"G Nowak","year":"1993","unstructured":"Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA (1993) Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 265(3):1380\u20131386","journal-title":"J Pharmacol Exp Ther"},{"key":"25_CR89","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","volume":"302","author":"NA Nu\u00f1ez","year":"2022","unstructured":"Nu\u00f1ez NA, Joseph B, Pahwa M, Kumar R, Resendez MG, Prokop LJ et al (2022) Augmentation strategies for treatment resistant major depression: a systematic review and network meta- analysis. J Affect Disord 302:385\u2013400. https:\/\/doi.org\/10.1016\/j.jad.2021.12.134","journal-title":"J Affect Disord"},{"key":"25_CR90","doi-asserted-by":"publisher","unstructured":"Nutt DJ, Hunt P, Schlag AK, Fitzgerald P (2024) The Australia story: current status and future challenges for the clinical applications of psychedelics. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.17398","DOI":"10.1111\/bph.17398"},{"key":"25_CR91","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","volume":"28(2)","author":"R Ochs-Ross","year":"2020","unstructured":"Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL et al (2020) Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry 28(2):121\u2013141. https:\/\/doi.org\/10.1016\/j.jagp.2019.10.008","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"25_CR92","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jagp.2021.09.014","volume":"30","author":"R Ochs-Ross","year":"2022","unstructured":"Ochs-Ross R, Wajs E, Daly EJ, Zhang Y, Lane R, Lim P et al (2022) Comparison of long-term efficacy and safety of esketamine nasal spray plus oral antidepressant in younger versus older patients with treatment-resistant depression: post-hoc analysis of SUSTAIN-2, a long-term open-label phase 3 safety and efficacy study. Am J Geriatr Psychiatry 30(5):541\u2013556. https:\/\/doi.org\/10.1016\/j.jagp.2021.09.014","journal-title":"Am J Geriatr Psychiatry"},{"key":"25_CR93","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-981-97-4402-2_3","volume":"1456","author":"B Olivier","year":"2024","unstructured":"Olivier B, Olivier JDA (2024) Efficacy, safety, and tolerability of psychedelics in treatment-resistant depression (TRD). Adv Exp Med Biol 1456:49\u201366. https:\/\/doi.org\/10.1007\/978-981-97-4402-2_3","journal-title":"Adv Exp Med Biol"},{"key":"25_CR94","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/978-1-0716-2083-0_20","volume":"179","author":"JDA Olivier","year":"2022","unstructured":"Olivier JDA, Janssen J, Pattij T, De Pr\u00eatre S, Olivier B (2022) Antidepressants, sexual behavior, and translational models for male sexual dysfunction: development of animal models, pharmacology, and genetics. NeuroMethods 179:451\u2013515. https:\/\/doi.org\/10.1007\/978-1-0716-2083-0_20","journal-title":"NeuroMethods"},{"key":"25_CR95","doi-asserted-by":"publisher","DOI":"10.1177\/1179069518800508","volume":"12","author":"DE Olson","year":"2018","unstructured":"Olson DE (2018) Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci 12:1179069518800508. https:\/\/doi.org\/10.1177\/1179069518800508","journal-title":"J Exp Neurosci"},{"issue":"6","key":"25_CR96","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00213-015-4198-1","volume":"233","author":"RS Oosting","year":"2016","unstructured":"Oosting RS, Chan JS, Olivier B, Banerjee P, Choi YK, Tarazi F (2016) Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats. Psychopharmacology (Berl) 233(6):1025\u20131034. https:\/\/doi.org\/10.1007\/s00213-015-4198-1. Epub 2016 Jan 13","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"25_CR97","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","volume":"37","author":"FL Os\u00f3rio","year":"2015","unstructured":"Os\u00f3rio FL, Sanches RF, Macedo LR, Santos RG, Maia-de-Oliveira JP, Wichert-Ana L et al (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Braz J Psychiatry. 37(1):13\u201320. https:\/\/doi.org\/10.1590\/1516-4446-2014-1496","journal-title":"Braz J Psychiatry."},{"issue":"4","key":"25_CR98","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA et al (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 49(4):655\u2013663. https:\/\/doi.org\/10.1017\/S0033291718001356","journal-title":"Psychol Med"},{"issue":"1","key":"25_CR99","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.euroneuro.2008.08.009","volume":"19","author":"GI Papakostas","year":"2009","unstructured":"Papakostas GI, Fava M (2009) Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19(1):34\u201340. https:\/\/doi.org\/10.1016\/j.euroneuro.2008.08.009","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"25_CR100","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","volume":"7","author":"T Passie","year":"2002","unstructured":"Passie T, Seifert J, Schneider U, Emrich HM (2002) The pharmacology of psilocybin. Addict Biol 7(4):357\u2013364. https:\/\/doi.org\/10.1080\/1355621021000005937","journal-title":"Addict Biol"},{"issue":"10","key":"25_CR101","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1177\/0091270004269521","volume":"44","author":"LE Pope","year":"2004","unstructured":"Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ, Sellers EM (2004) Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol 44(10):1132\u20131142. https:\/\/doi.org\/10.1177\/0091270004269521","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"25_CR102","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/02698811231182602","volume":"37","author":"C Pronovost-Morgan","year":"2023","unstructured":"Pronovost-Morgan C, Hartogsohn I, Ramaekers JG (2023) Harnessing placebo: lessons from psychedelic science. J Psychopharmacol 37(9):866\u2013875. https:\/\/doi.org\/10.1177\/02698811231182602","journal-title":"J Psychopharmacol"},{"key":"25_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120092","volume":"434","author":"DF Quach","year":"2022","unstructured":"Quach DF, de Leon VC, Conway CR (2022) Nitrous oxide: an emerging novel treatment for treatment-resistant depression. J Neurol Sci 434:120092. https:\/\/doi.org\/10.1016\/j.jns.2021.120092","journal-title":"J Neurol Sci"},{"issue":"9","key":"25_CR104","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT et al (2023) Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 330(9):843\u2013853. https:\/\/doi.org\/10.1001\/jama.2023.14530","journal-title":"JAMA"},{"key":"25_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2023.110869","volume":"129","author":"P Rech","year":"2024","unstructured":"Rech P, Custodio RR, Uggioni MLR, Prestes GS, Mar\u00e7al F, Silveira VP et al (2024) Use of nitrous oxide in the treatment of major depressive disorder and treatment-resistant major depressive disorder: a systematic review and meta-analysis nitrous oxide in depressive disorders. Prog Neuro-Psychopharmacol Biol Psychiatry 129:110869. https:\/\/doi.org\/10.1016\/j.pnpbp.2023.110869","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"14","key":"25_CR106","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","volume":"389","author":"A Reif","year":"2023","unstructured":"Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu DJ et al (2023) Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med 389(14):1298\u20131309. https:\/\/doi.org\/10.1056\/NEJMoa2304145","journal-title":"N Engl J Med"},{"issue":"12","key":"25_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103818","volume":"28","author":"TG Rhee","year":"2023","unstructured":"Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST (2023) Psychedelic renaissance: revitalized potential therapies for psychiatric disorders. Drug Discov Today 28(12):103818. https:\/\/doi.org\/10.1016\/j.drudis.2023.103818","journal-title":"Drug Discov Today"},{"issue":"1","key":"25_CR108","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1124\/jpet.103.049882","volume":"306","author":"J Riba","year":"2003","unstructured":"Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ (2003) Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 306(1):73\u201383. https:\/\/doi.org\/10.1124\/jpet.103.049882","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"25_CR109","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1176\/appi.ajp.20230172","volume":"180","author":"BL Roth","year":"2023","unstructured":"Roth BL, Gumpper RH (2023) Psychedelics as transformative therapeutics. Am J Psychiatry 180(5):340\u2013347. https:\/\/doi.org\/10.1176\/appi.ajp.20230172","journal-title":"Am J Psychiatry"},{"issue":"1","key":"25_CR110","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"RF Sanches","year":"2016","unstructured":"Sanches RF, de Lima Os\u00f3rio F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L et al (2016) Antidepressant effects of a single dose of Ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol 36(1):77\u201381. https:\/\/doi.org\/10.1097\/JCP.0000000000000436","journal-title":"J Clin Psychopharmacol"},{"key":"25_CR111","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","volume":"145","author":"C Sanchez","year":"2015","unstructured":"Sanchez C, Asin KE, Artigas F (2015) Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 145:43\u201357. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.07.001","journal-title":"Pharmacol Ther"},{"issue":"6","key":"25_CR112","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1176\/appi.ajp.2019.19040423","volume":"176","author":"AF Schatzberg","year":"2019","unstructured":"Schatzberg AF (2019) A word to the wise about intranasal esketamine. Am J Psychiatry 176(6):422\u2013424. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19040423","journal-title":"Am J Psychiatry"},{"key":"25_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2025.104413","volume":"106","author":"A Seraj","year":"2025","unstructured":"Seraj A, Reyazuddin M, Gaur RK, Andrade C (2025) Oral ketamine for rapid reduction of suicidal ideation in major depressive disorder: A midazolam-controlled randomized clinical trial. Asian J Psychiatr 106:104413. https:\/\/doi.org\/10.1016\/j.ajp.2025.104413","journal-title":"Asian J Psychiatr"},{"issue":"12","key":"25_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126804","volume":"25","author":"H Shafique","year":"2024","unstructured":"Shafique H, Demers JC, Biesiada J, Golani LK, Cerne R, Smith JL et al (2024) (R)-(-)-ketamine: the promise of a novel treatment for psychiatric and neurological disorders. Int J Mol Sci 25(12):6804. https:\/\/doi.org\/10.3390\/ijms25126804","journal-title":"Int J Mol Sci"},{"key":"25_CR115","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.tips.2009.09.002","volume":"30","author":"P Skolnick","year":"2009","unstructured":"Skolnick P, Popik P, Trullas R (2009) Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30:563\u2013569. https:\/\/doi.org\/10.1016\/j.tips.2009.09.002","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"25_CR116","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/jnc.15540","volume":"162","author":"ST Slocum","year":"2022","unstructured":"Slocum ST, DiBerto JF, Roth BL (2022) Molecular insights into psychedelic drug action. J Neurochem 162(1):24\u201338. https:\/\/doi.org\/10.1111\/jnc.15540","journal-title":"J Neurochem"},{"issue":"7","key":"25_CR117","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/02698811231154852","volume":"37","author":"J Sloshower","year":"2023","unstructured":"Sloshower J, Skosnik PD, Safi-Aghdam H, Pathania S, Syed S, Pittman B et al (2023) Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial. J Psychopharmacol 37(7):698\u2013706. https:\/\/doi.org\/10.1177\/02698811231154852","journal-title":"J Psychopharmacol"},{"issue":"4","key":"25_CR118","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.mulmdd3048sho","volume":"84","author":"ME Thase","year":"2023","unstructured":"Thase ME (2023) Have effective antidepressants finally arrived? Developments in major depressive disorder therapy. J Clin Psychiatry 84(4):mulmdd3048sho. https:\/\/doi.org\/10.4088\/JCP.mulmdd3048sho","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"25_CR119","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14052wc1c","volume":"76","author":"ME Thase","year":"2015","unstructured":"Thase ME, Schwartz TL (2015) Using mechanism of action to choose medications for treatment-resistant depression. J Clin Psychiatry 76(9):e1147","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"25_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-j","volume":"185","author":"R Trullas","year":"1990","unstructured":"Trullas R, Skolnick P (1990) Eur J Pharmacol 185(1):1\u201310. https:\/\/doi.org\/10.1016\/0014-2999(90)90204-j","journal-title":"Eur J Pharmacol"},{"issue":"16","key":"25_CR121","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2416106122","volume":"122","author":"JR Tuck","year":"2025","unstructured":"Tuck JR, Dunlap LE, Khatib YA, Hatzipantelis CJ, Weiser Novak S, Rahn RM et al (2025) Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential. Proc Natl Acad Sci USA 122(16):e2416106122. https:\/\/doi.org\/10.1073\/pnas.2416106122","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"25_CR122","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","volume":"24","author":"F Tyl\u0161","year":"2014","unstructured":"Tyl\u0161 F, P\u00e1len\u00ed\u010dek T, Hor\u00e1\u010dek J (2014) Psilocybin\u2014summary of knowledge and new perspectives. Eur Neuropsychopharmacol 24(3):342\u2013356","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"25_CR123","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1177\/02698811221082442","volume":"36","author":"JGC Van Amsterdam","year":"2022","unstructured":"Van Amsterdam JGC, Nabben T, van den Brink W (2022) Increasing recreational nitrous oxide use: should we worry? A narrative review. J Psychopharmacol 36(8):943\u2013950. https:\/\/doi.org\/10.1177\/02698811221082442","journal-title":"J Psychopharmacol"},{"issue":"3","key":"25_CR124","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3892\/etm.2023.11810","volume":"25","author":"O Vasiliu","year":"2023","unstructured":"Vasiliu O (2023) Esketamine for treatment-resistant depression: a review of clinical evidence (review). Exp Ther Med 25(3):111. https:\/\/doi.org\/10.3892\/etm.2023.11810","journal-title":"Exp Ther Med"},{"key":"25_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809","volume":"56","author":"R von Rotz","year":"2022","unstructured":"von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, J\u00e4ncke L, Preller KH, Vollenweider FX (2022) Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinMed 56:101809. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101809","journal-title":"EClinMed"},{"issue":"3","key":"25_CR126","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891","volume":"81","author":"E Wajs","year":"2020","unstructured":"Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P et al (2020) Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry 81(3):19m12891","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"25_CR127","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/JCP.0000000000001738","volume":"43","author":"PR Wang","year":"2023","unstructured":"Wang PR, Yavi M, Lee H, Kotb Y, Shora L, Park LT et al (2023) An open-label study of adjunctive dextromethorphan\/quinidine in treatment-resistant depression. J Clin Psychopharmacol 43(5):422\u2013427. https:\/\/doi.org\/10.1097\/JCP.0000000000001738","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"25_CR128","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1001\/jamapsychiatry.2023.4945","volume":"81","author":"ST Wilkinson","year":"2024","unstructured":"Wilkinson ST, Palamar JJ, Sanacora G (2024) The rapidly shifting ketamine landscape in the US. JAMA Psychiatry 81(3):221\u2013222. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.4945","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"25_CR129","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S2215-0366(15)00579-9","volume":"3","author":"LM Williams","year":"2016","unstructured":"Williams LM (2016) Precision psychiatry: a neural circuit taxonomy for depression and anxiety. Lancet Psychiatry 3(5):472\u2013480. https:\/\/doi.org\/10.1016\/S2215-0366(15)00579-9","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"25_CR130","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H et al (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 175(12):1205\u20131215. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18020138","journal-title":"Am J Psychiatry"},{"key":"25_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2022.114867","volume":"317","author":"D Yan","year":"2022","unstructured":"Yan D, Liu B, Wei X, Ou W, Liao M, Ji S et al (2022) Efficacy and safety of nitrous oxide for patients with treatment-resistant depression, a randomized controlled trial. Psychiatry Res 317:114867. https:\/\/doi.org\/10.1016\/j.psychres.2022.114867","journal-title":"Psychiatry Res"},{"issue":"1","key":"25_CR132","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/bdd.336","volume":"24","author":"Y Yanagihara","year":"2003","unstructured":"Yanagihara Y, Ohtani M, Kariya S, Uchino K, Hiraishi T, Ashizawa N et al (2003) Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 24(1):37\u201343. https:\/\/doi.org\/10.1002\/bdd.336","journal-title":"Biopharm Drug Dispos"},{"issue":"8","key":"25_CR133","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.biopsych.2018.05.007","volume":"84","author":"C Yang","year":"2018","unstructured":"Yang C, Kobayashi S, Nakao K, Dong C, Han M, Qu Y et al (2018) AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-norketamine. Biol Psychiatry 84(8):591\u2013600. https:\/\/doi.org\/10.1016\/j.biopsych.2018.05.007","journal-title":"Biol Psychiatry"},{"issue":"7604","key":"25_CR134","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI et al (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533(7604):481\u2013486. https:\/\/doi.org\/10.1038\/nature17998","journal-title":"Nature"},{"issue":"8","key":"25_CR135","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63(8):856\u2013864. https:\/\/doi.org\/10.1001\/archpsyc.63.8.856","journal-title":"Arch Gen Psychiatry"},{"key":"25_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109305","volume":"222","author":"K Zhang","year":"2023","unstructured":"Zhang K, Yao Y, Hashimoto K (2023) Ketamine and its metabolites: potential as novel treatments for depression. Neuropharmacology 222:109305. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109305","journal-title":"Neuropharmacology"},{"key":"25_CR137","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13699","volume":"82(2)","author":"M Zhdanava","year":"2021","unstructured":"Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P et al (2021) The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry 82(2):20m13699. https:\/\/doi.org\/10.4088\/JCP.20m13699","journal-title":"J Clin Psychiatry"}],"container-title":["Advances in Experimental Medicine and Biology","Understanding Depression"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-95-6872-7_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:32:43Z","timestamp":1777242763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-95-6872-7_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9789819568710","9789819568727"],"references-count":137,"URL":"https:\/\/doi.org\/10.1007\/978-981-95-6872-7_25","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 April 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) have no competing interests to declare that are relevant to the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The author(s) declare that this manuscript does not include primary research with human participants.The author(s) declare that this manuscript does not include primary studies involving animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}